 Theresa Medina
Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 11 | 2025 | 759 | 1.680 |
Why?
| | Skin Neoplasms | 6 | 2025 | 848 | 1.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 153 | 0.810 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 342 | 0.680 |
Why?
| | Mucous Membrane | 2 | 2024 | 128 | 0.320 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 49 | 0.310 |
Why?
| | Immunotherapy | 2 | 2024 | 665 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1958 | 0.250 |
Why?
| | Ipilimumab | 1 | 2025 | 40 | 0.230 |
Why?
| | Toll-Like Receptor 9 | 1 | 2025 | 37 | 0.220 |
Why?
| | Thymus Gland | 1 | 2025 | 311 | 0.210 |
Why?
| | Cancer Vaccines | 1 | 2025 | 161 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 58 | 0.210 |
Why?
| | Organoids | 1 | 2025 | 144 | 0.200 |
Why?
| | Telomerase | 1 | 2025 | 246 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 264 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 76 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 102 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 198 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8318 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5411 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 59 | 0.140 |
Why?
| | Neoplasms | 2 | 2025 | 2900 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2025 | 1993 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 72 | 0.120 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 66 | 0.120 |
Why?
| | Aged | 7 | 2025 | 26096 | 0.120 |
Why?
| | Middle Aged | 9 | 2025 | 36126 | 0.120 |
Why?
| | Exome | 1 | 2017 | 227 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 212 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 932 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 974 | 0.090 |
Why?
| | Female | 10 | 2025 | 78636 | 0.090 |
Why?
| | Adult | 5 | 2025 | 40665 | 0.080 |
Why?
| | Humans | 14 | 2025 | 145140 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1320 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2021 | 117 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3740 | 0.080 |
Why?
| | Male | 7 | 2025 | 72664 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1763 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 992 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 61 | 0.070 |
Why?
| | Uterine Neoplasms | 1 | 2008 | 98 | 0.060 |
Why?
| | Mutation | 1 | 2017 | 4071 | 0.060 |
Why?
| | Mice | 4 | 2025 | 18303 | 0.050 |
Why?
| | Hutchinson's Melanotic Freckle | 1 | 2024 | 3 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2025 | 271 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 105 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 221 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 187 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 272 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 125 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 438 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1264 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2021 | 173 | 0.040 |
Why?
| | Animals | 4 | 2025 | 37952 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 819 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 17247 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 3539 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 396 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 679 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1467 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 530 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1488 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4552 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3616 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 83 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4310 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 38 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2008 | 273 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 158 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 505 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 977 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2168 | 0.010 |
Why?
|
|
Medina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|